Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease
Autor: | Apostolia Papalexandri, Despina Mallouri, Aliki Tsompanakou, Anastasios Ilias, Nikoleta Pasteli, Ioannis Batsis, Achilles Anagnostopoulos, Anna Vardi, Ioanna Karafoulidou, Styliani Papaemmanouil, Ioanna Sakellari, Michalis Iskas, Eleni Gavriilaki, Andriana Lazaridou |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male medicine.medical_specialty Thrombotic microangiopathy Graft vs Host Disease Human leukocyte antigen Gastroenterology Fibrin Young Adult 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Prospective Studies Hematology biology Thrombotic Microangiopathies business.industry Mortality rate Hematopoietic Stem Cell Transplantation Endothelial Cells Thrombosis Middle Aged medicine.disease digestive system diseases Transplantation Intestinal Diseases Graft-versus-host disease 030220 oncology & carcinogenesis biology.protein Female Differential diagnosis Gastrointestinal Hemorrhage business 030215 immunology |
Zdroj: | International Journal of Hematology. 110:529-532 |
ISSN: | 1865-3774 0925-5710 |
Popis: | Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT) with multisystem involvement. Cases of TMA in the intestinal vasculature (intestinal TMA/iTMA) have been reported. We hypothesized that iTMA is a distinct entity from TA-TMA. To test this hypothesis, we prospectively recruited allo-HCT recipients with an indication for endoscopy. Among 20 patients, histological features of iTMA, including loss of glands, total denudation of mucosa, apoptosis and detachment of endothelial cells, mucosal hemorrhage, intraluminal fibrin and microthrombi were found in six. Only 2/6 were classified as GVHD/TA-TMA, while the other 4 as GVHD/no TA-TMA. Gastro-intestinal symptoms were similar between the patients with or without iTMA. With a median follow-up of 11.1 (2.1-67.5) months, 1-year overall survival was 22.2% for iTMA, 55% for GVHD and 60% for TA-TMA. On multivariate analysis, independent unfavorable predictors of OS were iTMA (p = 0.048), HLA mismatched donors (p = 0.008) and gastro-intestinal bleeding (p = 0.021). In conclusion, iTMA emerges as a novel distinct entity in patients with GVHD and/or TA-TMA. Distinct histological features may be useful in differential diagnosis of these severe HCT complications. The higher mortality rates of iTMA than TA-TMA highlight the need for further investigation of this condition. |
Databáze: | OpenAIRE |
Externí odkaz: |